Biomedical subjects

H Ishihara

Publications and source records attributed to H Ishihara.

687 records · Page 39Linked to original sources

PubMedDate not supplied

Plasma levels of endotoxin and anaphylatoxin in patients with multiple organ failure.

Plasma concentrations of endotoxin and anaphylatoxins were studied inpatients with multiple organ failure (MOF). Thirty one blood samples from nine patients with MOF and twenty samples from preoperative patients as control were determined. The average plasma concentration of endotoxin was 188.7 +/- 37.0 pg-ml-1 (Mean + S.E.) in MOF patients and 12.4 +/- 3.3 pg.ml-1 in control patients (p less than 0.05). Plasma anaphylatoxin (C3a, C5a) levels increased significantly and C4 level decreased in MOF patients as compared with those in control patients. However, no significant correlation was found between plasma endotoxin and anaphylatoxin levels. Endotoxin does not seem to be a major factor in activating of the complement system in patients with MOF.

Adult↗

PubMedDate not supplied

IFN-beta inhibition of etoposide resistance acquisition in vitro: studies using a human glioblastoma cell line.

The inhibition by IFN-beta of acquired resistance to the epipodophillotoxin etoposide was studied using a human glioblastoma cell line, T98G. T98G cells were exposed to either etoposide alone or both etoposide and IFN-beta, and after subculture, the same two series of drug exposure were repeated. Degree of level of resistance was tested by the response of the cells to etoposide and changes in their DNA histograms. Furthermore, topoisomerase II in each set of cells was subjected to fluorescence staining with monoclonal anti-topoisomerase II antibody, and the amount of fluorescence was measured by flow cytometry. Secondary etoposide exposure showed less cytotoxicity when the first exposure was to etoposide alone. In contrast, the cytotoxicity was almost the same as that after the first exposure when IFN-beta was added. Resistance to etoposide may result from qualitative or quantitative alterations in the target enzyme, topoisomerase II. The present results show that resistant cells have less topoisomerase II than sensitive cells, suggesting that IFN-beta inhibits the acquisition of resistance to etoposide by suppressing the alteration in topoisomerase II. The inhibition of acquired resistance to etoposide by IFN-beta suggests that continuous and repeated chemotherapy for glioblastoma and other malignant tumors may be clinically advantageous.

Antibodies, Monoclonal↗

PubMedDate not supplied

Elimination of FK-506 by continuous hemodiafiltration in a liver transplant patient.

A liver transplant patient who developed renal failure postoperatively was treated using continuous hemodiafiltration (CHDF). Doses ranging from 0.01 to 0.06 mg/kg/day of FK-506 had been administered intravenously. FK-506 concentrations before and after the filter, and in the ultradiafiltrate were 45.3 +/- 2.9, 56.0 +/- 5.3, and 9.1 +/- 3.1 ng/ml (mean, +/- S.D.), respectively. The filtration rate was 23.6 +/- 6.4%, and extracted FK-506 amounted to 522.0 micrograms (11.3% of administered dose). A part of the FK-506 administered was eliminated through the filter during CHDF.

Acute Kidney Injury↗